clinic
microbiolog
laboratori
play
critic
role
diagnosi
manag
patient
lower
respiratori
tract
infect
provid
pathogen
detect
identif
suscept
test
laboratori
provid
basi
optim
empir
antimicrobi
therapi
individu
tailor
regimen
microbiolog
laboratori
also
provid
epidemiolog
data
assist
hospit
epidemiologist
prevent
detect
investig
termin
nosocomi
outbreak
correctli
promptli
use
inform
provid
clinic
microbiolog
laboratori
improv
clinic
outcom
reduc
unnecessari
util
antibiot
prevent
nosocomi
transmiss
primari
aim
chapter
assist
clinician
effici
effect
util
resourc
clinic
microbiolog
laboratori
diagnosi
caus
infect
lower
respiratori
tract
chapter
assum
clinic
laboratori
use
valid
method
report
qualityassur
result
delv
technic
oper
aspect
clinic
microbiolog
laboratori
addit
inform
laboratori
oper
reader
refer
latest
edit
manual
clinic
microbiolog
american
societi
microbiolog
decis
order
diagnost
test
hing
whether
result
like
affect
clinician
treatment
decis
clinician
certain
patient
diseas
base
clinic
present
preval
high
pretest
probabl
decis
treat
like
alter
test
result
test
order
similarli
test
order
clinician
high
degre
priori
certainti
patient
diseas
decis
treat
like
alter
test
result
test
use
clinician
uncertain
probabl
diseas
result
sway
physician
decis
treatment
addit
pretest
probabl
sever
factor
affect
decis
exampl
therapi
come
low
harm
term
toxic
dollar
cost
select
resist
treat
patient
without
test
may
appropri
diagnost
low
sensit
ie
test
posit
low
percentag
patient
diseas
test
may
lead
inappropri
decis
treat
similarli
diagnost
low
specif
ie
test
posit
high
percentag
patient
without
diseas
test
may
lead
unnecessari
treatment
determin
clinic
suspicion
uncertain
enough
benefit
particular
diagnost
involv
interplay
cost
accuraci
diagnost
test
pretest
probabl
diseas
benefit
harm
treatment
clinician
play
critic
role
notifi
microbiolog
laboratori
hospit
infect
control
epidemiologist
virul
transmiss
agent
suspect
caus
diseas
alert
laboratori
staff
reduc
exposur
risk
laboratori
staff
handl
specimen
cultur
harbor
highli
virul
pathogen
list
pathogen
shown
tabl
specimen
patient
infecti
diseas
handl
onsit
laboratori
accord
guidelin
develop
local
nation
public
health
offici
specimen
potenti
contain
select
highrisk
agent
bacillu
anthraci
spore
francisella
tularensi
yersinia
pesti
variola
major
hemorrhag
fever
virus
clostridium
botulinum
toxin
directli
sent
public
health
laboratori
appropri
contain
facil
diagnost
tool
appli
make
diagnosi
pathogen
handl
onsit
laboratori
still
requir
laboratori
notif
includ
coccidioid
brucella
speci
cultur
associ
high
risk
laboratoryassoci
infect
although
technologist
expect
handl
specimen
microbiolog
cultur
use
univers
precaut
accident
exposur
happen
especi
find
unexpect
therefor
laboratori
notif
serv
alert
staff
protect
potenti
exposur
highli
transmiss
agent
local
sampl
storag
practic
case
addit
test
need
perform
gener
steril
specimen
tissu
sampl
aspir
valuabl
diagnost
absenc
contamin
commens
organ
ensur
organ
detect
like
repres
true
pathogen
histopatholog
examin
tissu
also
provid
inform
immunopatholog
characterist
infecti
process
howev
major
diagnost
challeng
lower
respiratori
tract
infect
lower
respiratori
tract
secret
usual
obtain
oropharynx
normal
contain
colonyform
unit
cfu
aerob
anaerob
bacteria
per
millilit
therefor
lower
respiratori
tract
secret
collect
microbiolog
examin
commonli
contamin
divers
bacteria
tabl
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
neisseria
meningitidi
also
pathogen
lower
respiratori
tract
oropharynx
also
contain
mycoplasma
pneumonia
aerob
actinomycet
includ
nocardia
nontubercul
mycobacteria
absenc
diseas
addit
aspir
even
minut
amount
oropharyng
secret
deliv
bolu
cfu
tracheobronchi
tree
distinct
case
colon
upper
respiratori
tract
pneumonia
easili
made
sputum
examin
cultur
anoth
challeng
oropharyng
secret
normal
contain
gramneg
bacilli
enterobacteriacea
pseudomona
acinetobact
often
becom
colon
mani
cfu
gramneg
bacilli
per
millilit
serious
ill
patient
requir
intens
care
patient
treat
antibiot
hospit
acut
pulmonari
inflammatori
diseas
chronic
alcohol
diabet
patient
institution
older
adult
chronic
ill
patient
hospit
patient
acut
leukemia
lastli
aspergillu
spore
present
environ
commonli
deposit
lower
respiratori
tract
may
recov
sputum
absenc
diseas
although
immunocompromis
patient
best
consid
find
serious
summari
lower
respiratori
tract
secret
collect
oropharynx
nearli
alway
contamin
resid
microflora
oral
caviti
divers
etiolog
agent
lower
respiratori
tract
infect
pose
number
diagnost
challeng
clinician
first
provid
must
formul
comprehens
yet
pragmat
differenti
diagnosi
take
account
clinic
present
immun
statu
exposur
histori
patient
clinician
must
order
correct
set
laboratori
test
ensur
collect
appropri
specimen
placement
correct
transport
contain
well
transport
laboratori
permiss
condit
test
improp
test
select
specimen
collect
could
reduc
analyt
sensit
specif
assay
perform
laboratori
syndrom
order
set
design
consid
common
pathogen
specif
syndrom
syndrom
order
set
incorpor
gener
guidelin
type
specimen
requir
collect
transport
avail
assay
pathogen
expect
given
clinic
set
syndrom
priorit
diagnost
maxim
yield
avoid
need
repeat
invas
procedur
order
set
also
serv
minim
risk
patient
lower
health
care
cost
howev
respons
clinician
ensur
specimen
requir
met
critic
test
priorit
especi
amount
specimen
materi
obtain
limit
multipl
test
order
tabl
show
syndrom
order
set
communityacquir
pneumonia
cap
hospitalacquir
ventilatorassoci
pneumonia
immunocompromis
host
pneumonia
respect
order
set
develop
address
local
epidemiolog
characterist
preanalyt
practic
may
tailor
serv
institut
clinician
also
familiar
tabl
see
tabl
see
tabl
see
tabl
see
tabl
see
tabl
definit
diagnosi
would
requir
steril
lung
tissu
demonstr
parenchym
invas
appropri
step
must
taken
obtain
specimen
highest
qualiti
microbiolog
test
expector
sputum
specimen
frequent
obtain
laboratori
diagnosi
lower
respiratori
tract
infect
import
proper
sputum
collect
document
laird
year
ago
studi
yield
mycobacterium
tuberculosi
accord
appear
cellular
composit
sputum
examin
first
requir
collect
goodqual
sputum
specimen
alert
cooper
patient
instruct
rins
mouth
water
even
brush
teeth
produc
lower
respiratori
tract
specimen
patient
must
encourag
cough
deepli
expector
specimen
lower
respiratori
tract
secret
infect
tuberculosi
tb
larger
sampl
volum
improv
sensit
cultur
specimen
collect
steril
leakproof
screwcap
contain
contain
transport
watertight
plastic
biohazard
bag
although
singl
sputum
specimen
may
suffici
establish
diagnosi
acut
bacteri
process
collect
seri
two
three
sputum
specimen
obtain
one
two
day
recommend
patient
suspect
mycobacteri
infect
patient
nonproduct
cough
suspect
mycobacteri
fungal
pneumocysti
jirovecii
infect
may
help
specimen
may
includ
endotrach
aspir
pleural
fluid
bronchoalveolar
lavag
bal
percutan
lung
aspir
lung
biopsi
use
bal
also
expand
includ
diagnosi
bacteri
pneumonia
especi
nosocomi
case
patient
cap
requir
admiss
hospit
use
protect
cathet
brush
bal
shown
provid
microbiolog
diagnos
obtain
noninvas
mean
although
littl
support
use
procedur
diagnos
cap
although
result
cultur
protect
cathet
brush
bal
specimen
quantit
similar
meduri
baselski
conclud
bal
specimen
provid
larger
repres
sampl
lower
respiratori
tract
secret
protect
cathet
brush
allow
microscop
analysi
cytocentrifug
bal
fluid
identifi
type
bacteria
present
demonstr
presenc
neutrophil
intracellular
organ
procedur
may
also
yield
addit
pathogen
obtain
noninvas
approach
much
work
also
done
use
bal
diagnosi
ventilatorassoci
pneumonia
see
chapter
children
year
age
suspect
tb
gastric
aspir
use
surrog
respiratori
sampl
histor
recommend
ph
gastric
aspir
neutral
sodium
bicarbon
transport
laboratori
howev
recent
studi
suggest
neutral
gastric
aspir
may
reduc
recoveri
tuberculosi
nasopharyng
aspir
also
use
diagnosi
tb
although
sensit
cultureconfirm
tb
lower
compar
induc
sputum
stool
sampl
children
pulmonari
tb
may
becom
specimen
choic
process
method
optim
concentr
tubercl
bacilli
specimen
type
may
aid
diagnosi
lower
respiratori
tract
infect
includ
whole
blood
blood
cultur
serum
antibodi
antigen
test
urin
antigen
test
blood
cultur
recommend
case
sever
pneumonia
posit
cap
less
nosocomi
pneumonia
import
note
larg
blood
volum
ml
three
set
blood
cultur
bottl
adult
necessari
maxim
sensit
blood
cultur
although
routin
blood
cultur
system
shown
highli
sensit
detect
candidemia
cryptococcemia
autom
blood
cultur
system
insensit
cultiv
monomorph
dimorph
mold
isol
mold
fastidi
bacteria
blood
requir
lysiscentrifug
method
isol
use
enrich
fungal
medium
bottl
pneumonia
recov
urin
cultur
mani
patient
pneumococc
pneumonia
urin
may
test
presenc
pneumococc
legionella
pneumophila
serogroup
antigen
fungal
antigen
test
urin
also
avail
diagnosi
histoplasmosi
blastomycosi
antigen
assay
discuss
later
chapter
clinic
laboratori
mandat
accredit
agenc
monitor
specimen
qualiti
quantiti
enforc
induc
sputum
product
inhal
aerosol
hyperton
salt
solut
collect
specimen
rapidli
deliv
laboratori
process
avoid
overgrowth
contamin
flora
compromis
microscop
detect
isol
pathogen
bacteria
penn
silberman
found
organ
observ
microscop
gramstain
smear
sputum
specimen
rel
number
cultur
chang
dramat
process
within
hour
collect
process
overnight
refriger
although
signific
differ
cultur
result
immedi
delay
cultur
studi
loss
reliabl
microscop
featur
signific
impact
interpret
cultur
result
process
delay
particularli
import
cultur
recoveri
slowgrow
mycobacteria
specimen
sent
laboratori
process
within
hour
refriger
day
refriger
possibl
sampl
treat
first
equal
volum
cetylpyridinium
bromid
cetylpyridinium
chlorid
sodium
chlorid
reduc
surviv
contamin
microorgan
preserv
viabil
tuberculosi
day
although
recoveri
fungi
optim
cultur
fresh
specimen
clinic
signific
fungi
appear
surviv
storag
day
longer
specimen
viral
cultur
ship
refriger
frozen
wherea
specimen
chlamydi
cultur
place
sucros
phosphat
medium
ship
frozen
although
univers
agreement
valu
anaerob
cultur
protect
cathet
brush
may
use
obtain
sampl
cultur
identif
organ
caus
anaerob
pleuropulmonari
diseas
essenti
transport
sampl
anaerob
vial
preserv
viabil
anaerob
organ
detect
respiratori
virus
nasopharyng
specimen
prefer
although
lower
respiratori
tract
specimen
may
necessari
detect
viral
infect
lower
respiratori
tract
number
method
collect
nasopharyng
specimen
includ
flock
tradit
swab
well
aspir
wash
flock
swab
contain
perpendicular
arrang
fiber
open
structur
creat
highli
absorb
thin
layer
capabl
effici
uptak
respiratori
sampl
elut
viral
transport
media
nasopharyng
flock
swab
shown
sensit
detect
respiratori
virus
tradit
swab
turn
nasopharyng
aspir
wash
shown
sensit
nasopharyng
flock
swab
howev
modest
gain
sensit
detect
respiratori
virus
use
aspir
wash
may
offset
eas
nasopharyng
specimen
collect
use
flock
swab
oropharyng
specimen
less
sensit
nasopharyng
specimen
though
combin
may
increas
respiratori
viru
detect
oropharyng
swab
may
also
use
detect
chlamydophila
pneumonia
pneumonia
legionella
speci
patient
critic
ill
immunocompromis
produc
expector
one
invas
approach
may
necessari
obtain
diagnost
sampl
reject
criteria
sampl
requir
met
common
caus
reject
includ
insuffici
sampl
quantiti
poor
sampl
qualiti
mislabel
sampl
bacteri
cultur
microscop
examin
sputum
endotrach
aspir
gram
stain
use
screen
sampl
adequ
qualiti
presenc
excess
squamou
epitheli
cell
per
lowpow
field
indic
oropharyng
contamin
therefor
ground
reject
bacteri
cultur
fig
although
earlier
criteria
adequaci
sputum
specimen
bacteri
cultur
also
requir
presenc
polymorphonuclear
leukocyt
neutrophil
number
neutrophil
sampl
longer
use
evalu
specimen
adequaci
endotrach
aspir
reject
screen
gramstain
smear
show
organ
mycobacteri
fungal
viral
cultur
cytolog
screen
determin
specimen
accept
enforc
contamin
commens
interfer
interpret
cultur
result
howev
presenc
respiratori
columnar
epitheli
cell
shown
improv
respiratori
viru
detect
direct
fluoresc
antibodi
dfa
test
clinic
microbiolog
laboratori
offer
broad
rang
assay
diagnosi
lower
respiratori
tract
infect
particular
pathogen
multipl
assay
may
avail
therefor
respons
clinician
choos
assay
best
perform
characterist
particular
specimen
type
tabl
summar
accuraci
assay
use
diagnosi
lower
respiratori
tract
infect
caus
bacteria
fungi
parasit
addit
clinician
must
familiar
turnaround
time
assay
optim
use
result
manag
patient
microscop
examin
lower
respiratori
tract
specimen
offer
rapid
approach
detect
identif
mani
pathogen
howev
discuss
earlier
major
limit
microscop
examin
distinguish
infect
colon
contamin
specimen
collect
oropharynx
addit
microscopi
lack
sensit
specimen
less
cfu
per
millilit
microscopi
routin
provid
valuabl
inform
qualiti
specimen
type
inflammatori
respons
present
specimen
demonstr
preponder
polymorphonuclear
leukocyt
ciliat
columnar
epitheli
cell
alveolar
macrophag
squamou
epitheli
cell
per
lowpow
field
repres
lower
respiratori
tract
secret
presenc
alveolar
macrophag
specif
marker
lower
respiratori
tract
secret
neutrophil
like
associ
significantli
lower
incid
oropharyng
contamin
find
neutrophil
intracellular
organ
consid
indic
activ
infecti
process
gramstain
smear
essenti
necessari
part
evalu
sputum
tracheal
aspir
determin
qualiti
accept
specimen
bacteri
cultur
provid
rapid
assess
like
etiolog
agent
pneumonia
although
gram
stain
might
also
suggest
presenc
mycobacteria
fungi
parasit
special
stain
order
pathogen
suspect
gram
stain
also
stain
squamou
epitheli
cell
ciliat
columnar
epitheli
cell
neutrophil
alveolar
macrophag
use
assess
specimen
qualiti
inflammatori
respons
tabl
show
criteria
use
laboratori
interpret
find
gram
stain
report
physician
although
imposs
correl
everi
stain
pattern
particular
pathogen
sever
gram
stain
pattern
pathognomon
particular
pathogen
clinic
entiti
tabl
accuraci
gram
stain
detect
infect
depend
stringenc
criteria
assess
patient
acut
cap
rein
colleagu
found
three
gramposit
lancetshap
diplococci
fig
correctli
predict
presenc
pneumococci
correspond
cultur
case
sensit
specif
respect
expect
improv
sensit
gram
stain
examin
lower
criteria
posit
result
reduc
specif
diagnosi
pneumococc
infect
similar
level
sensit
gramstain
smear
report
other
identifi
pneumococci
well
h
influenza
fig
sputum
specimen
patient
acut
cap
diagnosi
pneumococc
pneumonia
combin
gramstain
smear
cultur
sputum
yield
correct
diagnosi
patient
receiv
less
hour
effect
antibiot
therapi
direct
examin
sputum
identif
organ
either
commens
caus
acidfast
stain
method
choic
visual
mycobacteria
respiratori
specimen
laboratori
may
use
either
carbolfuchsin
fluorochrom
stain
mycobacteria
tabl
show
criteria
use
laboratori
report
find
acidfast
stain
studi
carbolfuchsinbas
stain
sensit
lower
compar
cultur
fluorochrom
stain
use
fluoresc
dye
auramin
auraminerhodamin
highlight
mycobacteria
averag
sensit
carbolfuchsin
therefor
method
recommend
world
health
organ
screen
sputum
smear
mycobacteria
sensit
acidfast
microscopi
depend
bacillari
burden
sampl
volum
host
immun
statu
stain
method
variabl
major
limit
factor
approxim
acidfast
bacilli
per
millilit
sputum
must
present
visual
light
microscopi
use
acidfast
stain
insensit
smear
microscopi
tb
therefor
necessit
use
sensit
method
cultur
nucleic
acid
test
addit
although
acidfast
stain
high
specif
distinguish
tuberculosi
complex
nontubercul
mycobacteria
carbolfuchsin
stain
also
stain
legionella
micdadei
also
known
tatlockia
micdadei
modifi
acidfast
stain
modifi
carbolfuchsin
stain
use
direct
stain
partial
acidfastposit
organ
nocardia
tsukamurella
rhodococcu
gordonia
immunofluoresc
examin
dfa
stain
altern
method
direct
visual
organ
diagnosi
legionellosi
usual
made
combin
direct
immunofluoresc
examin
cultur
respiratori
specimen
antigen
antibodi
test
dfa
stain
perform
sputum
endotrach
aspir
bronchial
wash
lung
tissu
specimen
sensit
rang
diagnosi
l
pneumophila
pneumonia
specif
fig
clinic
technic
variabl
account
broad
rang
sensit
test
accuraci
method
detect
pneumonia
due
legionella
speci
less
precis
known
absenc
support
evid
posit
dfa
result
gener
accept
suffici
diagnosi
legionella
infect
confirmatori
measur
undertaken
dfa
test
also
found
sensit
specif
detect
chlamydia
trachomati
nasopharyng
specimen
infant
pneumonia
also
appli
sputum
bal
detect
p
jirovecii
caus
agent
pneumocysti
pneumonia
silver
stain
direct
immunofluoresc
indirect
immunofluoresc
diffquik
modifi
giemsa
stain
found
greater
sensit
detect
p
jirovecii
induc
sputum
bal
sampl
human
immunodefici
viru
hiv
infect
patient
fig
stain
techniqu
lower
sensit
patient
infect
hiv
dfa
consist
sensit
stain
techniqu
dfa
also
appli
respiratori
secret
diagnosi
respiratori
viru
infect
dfa
test
perform
hour
typic
sensit
rapid
antigen
test
howev
dfa
test
respiratori
virus
requir
high
level
technic
interpret
expertis
difficult
adapt
high
throughput
requir
pandem
highvolum
test
remain
less
sensit
realtim
polymeras
chain
reaction
pcr
dfa
viral
detect
phase
mani
clinic
laboratori
rapid
sensit
multiplex
molecular
diagnost
respiratori
viru
test
becom
avail
visual
fungal
element
respiratori
secret
requir
use
special
stain
histor
potassium
hydroxid
use
degrad
host
tissu
visual
fungal
element
fig
calcofluor
white
stain
fluorochrom
bind
chitin
cellulos
present
fungal
cell
wall
commonli
ad
potassium
hydroxid
use
alon
provid
better
delin
fungal
element
fig
tabl
list
stain
pattern
suggest
certain
fungal
pathogen
import
note
identif
fungi
base
microscop
appear
fungal
element
lung
tissu
secret
subject
error
definit
identif
must
defer
cultur
identif
pulmonari
parasit
strongyloid
stercorali
paragonimu
spp
typic
made
microscop
examin
respiratori
secret
stercorali
larva
rare
egg
seen
stain
suffici
larg
like
found
use
lowpow
object
fig
diagnosi
microfilaria
caus
tropic
pulmonari
eosinophilia
requir
peripher
blood
parasit
examin
nightli
blood
sampl
parasit
typic
circul
blood
night
coincid
activ
insect
vector
echinococcu
cyst
may
detect
pulmonari
cyst
fluid
entamoeba
histolytica
may
seen
associ
pleural
diseas
ameb
liver
abscess
erod
diaphragm
microbiolog
cultur
respiratori
specimen
allow
definit
identif
suspect
pathogen
permit
determin
bacteri
mycobacteri
yeast
suscept
antimicrobi
agent
cultiv
particular
group
speci
microorgan
laboratori
must
inocul
process
sampl
one
cultur
media
supplement
nutrient
suitabl
cultiv
desir
microorgan
inhibitor
select
inhibit
undesir
organ
clinician
must
therefor
awar
although
mani
organ
grow
routin
aerob
anaerob
cultur
number
respiratori
pathogen
mycoplasma
legionella
mycobacterium
nocardia
rhodococcu
histoplasma
capsulatum
requir
pathogenspecif
growth
condit
growth
supplement
temperatur
carbon
dioxid
requir
incub
time
specifi
fastidi
pathogen
part
differenti
diagnosi
exampl
legionella
speci
requir
cultur
media
supplement
lcystein
buffer
charcoal
yeast
extract
slowgrow
mycobacteria
requir
media
enrich
lipid
extract
antimicrobi
limit
growth
oral
commens
h
capsulatum
requir
extend
incub
time
week
although
nocardia
speci
grow
well
mycobacteri
cultur
media
well
ordinari
bacteri
fungal
cultur
media
optim
recoveri
clinic
specimen
obtain
use
buffer
charcoal
yeast
extract
cultur
medium
isol
legionella
laboratori
commonli
use
semiquantit
cultur
method
report
number
coloni
present
consecut
streak
quadrant
use
grade
system
tabl
list
criteria
report
semiquantit
cultur
import
note
semiquantit
cultur
method
volum
specimen
cultur
standard
quantit
cultur
also
perform
certain
respiratori
specimen
protect
cathet
brush
specimen
bal
fluid
nonetheless
random
trial
found
mechan
ventil
patient
pneumonia
use
quantit
bal
nonquantit
endotrach
aspir
cultur
result
similar
clinic
outcom
although
patient
known
colon
infect
pseudomona
aeruginosa
methicillinresist
staphylococcu
aureu
broadbas
bud
yeast
see
fig
narrowbas
bud
yeast
fig
exclud
antibiot
withheld
result
cultur
avail
bacteria
present
quantiti
greater
cfuml
cultur
protect
cathet
brush
quantiti
greater
cfuml
cultur
bal
fluid
defin
laboratori
posit
identifi
test
suscept
appropri
antimicrobi
agent
diagnost
valu
break
point
bacteri
growth
ie
cfu
ml
depend
type
microbiolog
process
use
also
relationship
two
variabl
concentr
pathogen
present
bal
fluid
degre
contamin
bronchoscop
channel
lavag
fluid
inject
aspir
variabl
affect
sensit
bal
specimen
includ
antibiot
administr
volum
lavag
fluid
inject
volum
fluid
retriev
diagnost
specif
depend
greatli
techniqu
use
minim
contamin
specimen
upper
respiratori
flora
discard
first
aliquot
aspir
fluid
mani
pathogen
lower
respiratori
tract
also
member
oropharyng
flora
cultur
result
must
correl
gram
stain
find
includ
presenc
absenc
polymorphonuclear
leukocyt
respiratori
pathogen
seen
gram
stain
predomin
typic
morpholog
characterist
within
outsid
polymorphonuclear
leukocyt
report
identifi
speci
level
upper
respiratori
colon
potenti
pathogen
microorgan
gramneg
bacilli
may
relat
actual
etiolog
agent
lower
respiratori
tract
infect
sputum
specimen
contamin
enterobacteriacea
aureu
oropharyng
secret
may
obscur
diagnosi
pneumococc
pneumonia
anaerob
pleuropulmonari
infect
even
tb
except
cryptococcu
yeast
consid
upper
respiratori
origin
routin
identifi
sensit
specif
cultur
depend
pathogen
burden
specimen
type
collect
method
cytolog
screen
criteria
appli
ensur
sampl
lower
respiratori
tract
secret
threshold
coloni
count
distinguish
infect
contamin
barrettconnor
show
patient
bacterem
pneumococc
pneumonia
pneumococci
isol
sputum
cultur
wherea
patient
moder
heavi
growth
anoth
potenti
pathogen
cultur
contrast
fungal
cultur
respiratori
specimen
posit
approxim
case
dissemin
chronic
pulmonari
histoplasmosi
better
understand
care
specimen
collect
cytolog
screen
specimen
discard
contamin
oropharyng
secret
use
result
gramstain
smear
guid
identif
isol
cultur
contribut
diagnost
valu
sputum
cultur
acut
pneumococc
pneumonia
import
clinician
knowledg
turnaround
time
test
includ
cultur
time
detect
posit
cultur
result
depend
number
organ
inoculum
replic
rate
pathogen
tabl
show
typic
turnaround
time
lower
respiratori
tract
pathogen
fecal
cultur
may
use
case
suspect
pulmonari
involv
stercorali
sputum
cytolog
variou
categori
organ
second
select
antibiot
test
report
determin
collabor
clsieucast
guidelin
hospit
formulari
infecti
diseas
specialist
pharmaci
infect
prevent
committe
third
antimicrobi
suscept
test
perform
pathogen
predict
suscept
profil
eg
streptococcu
pyogen
current
suscept
penicillin
suscept
test
need
specif
antibiot
organ
intrins
resist
antibiot
eg
enterobact
spp
klebsiella
spp
citrobact
spp
serratia
spp
intrins
resist
ampicillin
bacteri
pathogen
lower
respiratori
tract
suscept
profil
predict
thu
antimicrobi
suscept
test
commonli
perform
pneumonia
aureu
h
influenza
catarrhali
enterobacteriacea
p
aeruginosa
nonfer
gramneg
rod
fourth
antimicrobi
suscept
test
measur
vitro
activ
factor
must
consid
determin
vivo
activ
includ
antimicrobi
pharmacokinet
pharmacodynam
patientspecif
factor
immun
statu
phenotyp
suscept
test
method
use
clinic
laboratori
consist
disk
diffus
method
gener
qualit
result
base
zone
size
bacteri
growth
inhibit
dilut
method
gener
quantit
result
minimum
inhibitori
concentr
result
gener
method
report
suscept
intermedi
resist
suscept
impli
organ
like
respond
treatment
antibiot
standard
dosag
intermedi
may
effect
higher
dose
use
eg
antibiot
use
concentr
site
infect
eg
fluoroquinolon
urinari
tract
infect
resist
impli
organ
like
respond
therapi
antibiot
interpret
criteria
suscept
intermedi
resist
specif
organismdrug
combin
well
pharmacokinet
eg
peak
serum
level
protein
bind
clearanc
rate
drug
pharmacodynam
eg
whether
rate
bacteri
kill
concentr
depend
characterist
drug
therefor
measur
minimum
inhibitori
concentr
alon
captur
multipl
consider
simpli
choos
drug
basi
lowest
minimum
inhibitori
concentr
suscept
report
recommend
genotyp
suscept
test
also
possibl
certain
pathogendrug
combin
monogen
mutat
accur
predict
resist
phenotyp
exampl
includ
meca
gene
methicillin
resist
staphylococcu
vana
vanb
vancomycin
resist
enterococcu
specif
rpob
mutat
rifampin
resist
tuberculosi
pathogen
isol
laboratori
reliabl
test
antimicrobi
suscept
organ
chlamydophila
mycoplasma
legionella
nontubercul
mycobacteria
mold
current
standard
test
method
interpret
criteria
pathogen
clinic
experi
use
consensu
guidelin
care
assess
patient
respons
antimicrobi
therapi
valuabl
optim
patient
manag
examin
fail
identifi
larva
agar
plate
method
look
track
bacteria
motil
larva
use
adjunct
standard
microscop
fecal
examin
may
six
time
sensit
viral
cultur
techniqu
previous
play
import
role
diagnosi
respiratori
viru
infect
howev
tradit
viral
cultur
labori
requir
signific
technic
interpret
expertis
allow
isol
limit
rang
diseasecaus
virus
long
turnaround
time
limit
clinic
util
shell
vial
cultur
improv
method
sampl
centrifug
onto
layer
cell
subsequ
detect
viral
antigen
shell
vial
cultur
particularli
use
mixtur
mink
lung
cell
provid
equival
improv
sensit
compar
tradit
cultur
rapid
turnaround
time
similar
respiratori
viru
dfa
routin
respiratori
viral
cultur
phase
mani
clinic
laboratori
widespread
avail
respiratori
viru
molecular
diagnost
test
howev
bal
sampl
transplant
recipi
immunocompromis
patient
shell
vial
cultur
use
human
fibroblast
cell
line
may
clinic
use
detect
cytomegaloviru
cmv
tradit
viral
cultur
may
use
recoveri
herp
simplex
viru
antimicrobi
suscept
test
perform
assist
clinician
select
appropri
target
antibiot
therapi
optim
clinic
outcom
sever
aspect
vitro
test
import
understand
first
test
method
interpret
result
must
done
accord
accept
standard
clinic
laboratori
standard
institut
clsi
us
food
drug
administr
fda
european
committe
antimicrobi
suscept
test
eucast
cmv
directli
respiratori
specimen
normal
immunocompromis
host
accuraci
studi
indic
assay
least
compar
better
convent
cultur
direct
antigen
andor
serolog
detect
method
especi
examin
respiratori
specimen
contain
low
number
pathogen
exampl
rapid
pcr
assay
appli
diagnosi
outbreak
chlamydia
psittaci
result
transmiss
infecti
agent
human
bird
purchas
store
outbreak
pcr
detect
case
cultur
compar
cultur
serolog
test
pcr
also
shown
sensit
method
detect
c
pneumonia
outbreak
cap
howev
nat
result
interpret
caution
nat
current
differenti
organ
inhabit
upper
airway
without
caus
diseas
respons
patient
ill
exampl
mention
pneumonia
c
pneumonia
pneumonia
may
inhabit
upper
airway
without
caus
diseas
similarli
lower
diagnost
specif
p
jirovecii
nat
like
due
detect
p
jirovecii
nucleic
acid
cyst
present
low
number
latent
state
pulmonari
tissu
asymptomat
patient
patient
cultureneg
infect
cultur
perform
tissu
biopsi
sampl
fixat
broadrang
pcr
assay
coupl
amplicon
sequenc
use
detect
identif
bacteri
fungal
dna
fresh
formalinfix
paraffinembed
ffpe
specimen
bacteri
ribosom
rna
gene
fungal
ribosom
rna
operon
encod
ribosom
subunit
gene
intern
transcrib
spacer
region
reliabl
frequent
use
target
identifi
bacteri
fungal
sequenc
respect
nat
sensit
higher
fresh
tissu
ffpe
specimen
exampl
fungal
sequenc
success
complet
specimen
perform
fresh
specimen
compar
perform
ffpe
specimen
despit
mani
advantag
direct
bacteri
fungal
identif
sequenc
clinician
must
awar
success
method
depend
amount
specimen
submit
eg
open
biopsi
versu
needl
biopsi
pathogen
burden
whether
fresh
versu
ffpe
tissu
test
imper
test
strictli
limit
sampl
obtain
steril
sourc
contamin
sampl
commens
organ
environment
spore
could
yield
falseposit
result
lead
mismanag
patient
sequenc
result
must
alway
correl
clinic
histopatholog
ancillari
test
result
antibodi
antigen
detect
ensur
clinic
accuraci
sequenc
result
diagnosi
respiratori
viru
infect
tabl
revolution
nucleic
acid
amplif
test
test
consid
sensit
current
method
viru
detect
includ
viral
cultur
dfa
test
discuss
earlier
well
rapid
antigen
test
discuss
later
follow
influenza
pandem
tremend
increas
avail
widespread
implement
realtim
pcr
assay
influenza
respiratori
recent
year
technolog
advanc
nucleic
acid
test
nat
instrument
autom
revolution
simplic
speed
accuraci
detect
fastidi
pathogen
directli
respiratori
specimen
mani
laboratori
test
replac
convent
less
sensit
labori
method
routin
use
uniqu
capabl
molecular
diagnost
test
need
rapid
sensit
detect
respiratori
pathogen
molecular
assay
continu
gain
increas
role
diagnosi
manag
patient
opportunist
communityacquir
pneumonia
nat
base
amplif
detect
nucleic
acid
target
specif
pathogen
interest
nat
offer
sever
advantag
convent
direct
examin
microbiolog
cultur
serolog
assay
first
nat
abil
detect
identifi
pathogen
rapidli
hour
second
nat
provid
mean
detect
microorgan
difficult
imposs
grow
cultur
certain
virus
exampl
difficult
cultiv
convent
culturebas
method
nat
enabl
detect
organ
clinic
specimen
third
nat
make
possibl
detect
pathogen
tuberculosi
resourcelimit
set
laboratori
infrastructur
cultur
lack
final
pathogen
nat
allow
determin
antimicrobi
suscept
directli
respiratori
tract
specimen
number
commerci
inhous
nat
avail
direct
detect
tuberculosi
sputum
assay
yield
result
hour
exampl
comparison
convent
cultur
tuberculosi
nat
high
sensit
specif
smearposit
respiratori
sampl
smearneg
cultureposit
specimen
nat
confirm
presenc
tuberculosi
sampl
week
earlier
cultur
sensit
improv
smearneg
sputa
assay
perform
one
two
addit
sampl
detect
tuberculosi
suscept
firstand
secondlin
drug
also
accomplish
directli
sputum
commerci
nat
detect
rifampin
isoniazid
resist
sensit
respect
base
improv
perform
nat
smear
microscopi
rapid
turnaround
time
compar
cultur
us
center
diseas
control
prevent
cdc
recommend
nat
test
perform
least
one
respiratori
specimen
patient
sign
symptom
pulmonari
tb
diagnosi
tb
consid
yet
establish
test
result
would
alter
case
manag
tb
control
activ
addit
world
health
organ
recommend
use
nat
screen
multidrugresist
tb
three
nat
commerci
avail
europ
elsewher
one
approv
fda
diagnost
method
also
describ
detect
nucleic
acid
c
pneumonia
pneumonia
l
pneumophila
dimorph
fungi
monomorph
fungi
p
jirovecii
toxoplasma
gondii
respiratori
virus
herp
simplex
viru
simplic
rapid
antigen
test
sensit
nucleic
acid
amplif
test
includ
xpert
flu
cepheid
sunnyval
ca
detect
influenza
b
hour
verigen
respiratori
viru
plu
nanospher
northbrook
il
detect
subtyp
influenza
b
detect
type
respiratori
syncyti
viru
rsv
less
hour
though
sensit
tradit
respiratori
viru
diagnost
xpert
flu
slightli
less
sensit
inhous
realtim
pcr
assay
perform
verigen
respiratori
viru
plu
appear
compar
inhous
realtim
pcr
assay
yet
compar
second
group
test
highcomplex
fdaclear
comprehens
respiratori
viru
panel
requir
separ
extract
pcr
amplif
step
multiplex
nucleic
acid
detect
test
includ
xtag
respiratori
viru
panel
luminex
austin
tx
xtag
xtag
rvp
fast
well
esensor
respiratori
viru
panel
genmark
diagnost
carlsbad
ca
xtag
rvp
achiev
highlevel
multiplex
combin
target
amplicon
label
univers
minim
crosshybrid
complementari
oligonucleotid
sequenc
flow
cytometr
detect
use
solutionphas
array
compos
spectral
distinct
microspher
approxim
hour
detect
influenza
includ
subtyp
influenza
b
rsv
rsv
b
parainfluenza
viru
human
metapneumoviru
adenoviru
rhinovirusenteroviru
compar
rvp
fast
shorter
time
result
hour
howev
detect
parainfluenza
virus
distinguish
rsv
type
sever
studi
compar
clinic
perform
xtag
rvp
found
xtag
rvp
fast
panel
sensit
tradit
respiratori
viru
test
methodolog
less
sensit
inhous
realtim
pcr
sensit
rvp
fast
note
assay
demonstr
low
sensit
adenovirus
distinguish
close
relat
picornavirus
rhinoviru
enteroviru
group
esensor
rvp
achiev
highlevel
multiplex
competit
hybrid
electrochem
detect
use
microfluid
devic
contain
array
singlestrand
oligonucleotid
captur
probe
approxim
hour
esensor
rvp
detect
influenza
includ
subtyp
influenza
b
rsv
rsv
b
parainfluenza
viru
human
metapneumoviru
adenoviru
c
adenoviru
rhinoviru
esensor
rvp
demonstr
compar
perform
inhous
realtim
pcr
includ
detect
adenoviru
rhinoviru
time
appear
sensit
multiplex
respiratori
viru
assay
xtag
esensor
rvp
assay
researchonli
version
version
approv
outsid
unit
state
offer
detect
parainfluenza
human
coronavirus
xtag
rvp
bocaviru
sever
acut
respiratori
syndrom
coronaviru
determin
clinic
util
expand
panel
requir
addit
studi
third
group
molecular
respiratori
viru
test
moder
complex
combin
simplic
virus
realtim
pcr
assay
includ
endors
cdc
well
numer
laboratorydevelop
commerci
produc
test
howev
inhous
realtim
pcr
test
high
complex
requir
experienc
highli
skill
staff
well
special
molecular
diagnost
laboratori
facil
furthermor
test
gener
batch
therebi
prolong
turnaround
time
reduc
clinic
util
final
realtim
pcr
allow
moder
level
multiplex
ie
use
primer
probe
detect
multipl
target
reaction
potenti
issu
detect
broad
rang
respiratori
virus
limit
number
reaction
address
issu
varieti
commerci
test
system
develop
though
singl
system
provid
comprehens
detect
clinic
relev
respiratori
virus
optim
sensit
format
perform
near
point
care
three
group
molecular
test
exist
differ
level
technic
personnel
demand
refer
moder
high
complex
establish
clinic
laboratori
improv
amend
one
group
molecular
test
includ
limit
respiratori
viru
panel
moder
complex
fdaclear
sampletoansw
platform
combin
speed
legionnair
diseas
urin
l
pneumophila
serogroup
antigen
high
neg
predict
valu
pool
sensit
ci
specif
ci
urin
antigen
l
pneumophila
detect
patient
legionnair
diseas
begin
first
day
symptom
continu
least
day
durat
antigenuria
reduc
antibiot
therapi
detect
day
especi
immunocompromis
patient
urinari
antigen
assay
limit
detect
infect
due
l
pneumophila
serogroup
legionella
serogroup
speci
detect
fungal
antigen
serum
urin
bodi
fluid
use
aid
diagnosi
infect
due
cryptococcu
neoforman
aspergillu
h
capsulatum
p
jirovecii
assay
detect
capsular
polysaccharid
c
neoforman
serum
cerebrospin
fluid
essenti
rapid
diagnosi
cryptococcosi
commerci
avail
assay
show
sensit
rang
specif
cryptococc
antigen
may
also
detect
pleural
fluid
bal
fluid
patient
cryptococc
pneumonia
serial
measur
serum
antigen
titer
time
use
manag
patient
pulmonari
cryptococcosi
cryptococc
antigen
may
fals
posit
due
presenc
rheumatoid
factor
heterophil
antibodi
ie
antibodi
produc
poorli
defin
antigen
weak
affin
multispecif
activ
fals
neg
due
prozon
effect
antigen
excess
local
infect
infect
poorli
encapsul
strain
low
organ
burden
sever
commerci
h
capsulatum
antigen
assay
variabl
accuraci
avail
diagnosi
histoplasmosi
polysaccharid
antigen
h
capsulatum
detect
urin
approxim
patient
dissemin
diseas
diffus
acut
pulmonari
histoplasmosi
recent
multicent
studi
identifi
antigenuria
patient
dissemin
histoplasmosi
patient
acut
histoplasmosi
patient
subacut
infect
patient
chronic
histoplasmosi
antigenemia
detect
patient
dissemin
infect
urinari
histoplasma
antigen
level
persist
ongo
activ
infect
becom
undetect
success
therapi
rise
relaps
infect
specif
histoplasma
antigen
assay
patient
nonfung
infect
healthi
control
howev
assay
known
yield
posit
result
patient
dissemin
infect
caus
blastomyc
dermatitidi
coccidioid
immiti
paracoccidioid
brasiliensi
aspergillu
penicillium
marneffei
cross
reactiv
assay
observ
patient
invas
candidiasi
cryptococcosi
opportunist
system
mycos
least
one
commerci
laboratori
offer
antigen
test
diagnosi
coccidioidomycosi
blastomycosi
test
exhibit
signific
cross
reaction
h
capsulatum
aspergillu
galactomannan
major
cell
wall
compon
fungu
detect
antigen
studi
mani
differ
clinic
situat
galactomannan
detect
serum
enzym
immunoassay
aid
speed
rapid
antigen
test
sensit
multiplex
capabl
xtag
esensor
rvp
present
one
assay
avail
categori
filmarray
respiratori
panel
biofir
diagnost
salt
lake
citi
ut
integr
sampl
prepar
nestedpcr
amplif
realtim
fluoresc
detect
analysi
singl
assay
pouch
hour
includ
less
minut
handson
time
assay
detect
influenza
includ
subtyp
influenza
b
rsv
parainfluenza
viru
human
metapneumoviru
adenoviru
rhinovirusenteroviru
human
coronavirus
addit
detect
three
bacteri
speci
bordetella
pertussi
c
pneumonia
pneumonia
clinic
perform
similar
xtag
demonstr
higher
sensit
tradit
respiratori
viru
test
methodolog
lower
sensit
compar
inhous
realtim
pcr
current
film
array
respiratori
panel
also
low
sensit
adenovirus
distinguish
rhinoviru
enteroviru
low
throughput
one
test
perform
instrument
time
howev
rapid
turnaround
eas
use
allow
laboratori
perform
multiplex
molecular
respiratori
viru
test
futur
expect
assay
categori
improv
sensit
specif
throughput
creat
optim
rapid
multiplex
molecular
respiratori
viru
test
given
varieti
nucleic
acid
test
current
avail
diagnosi
respiratori
viru
infect
rapid
develop
new
nat
import
commun
laboratori
confirm
virus
includ
local
panel
expect
turnaround
time
local
test
perform
characterist
furthermor
note
nasopharyng
swab
aspiratewash
specimen
type
receiv
fda
clearanc
far
also
import
verifi
local
laboratori
valid
use
lower
respiratori
tract
specimen
test
system
send
sampl
test
diagnosi
lower
respiratori
tract
infect
aid
detect
pathogenspecif
antigen
serum
bodi
fluid
antigen
detect
offer
altern
direct
examin
infect
tissu
may
play
role
detect
pathogen
grow
poorli
cultur
urinari
antigen
assay
may
valu
adult
pneumonia
l
pneumophila
infect
metaanalysi
studi
use
composit
cultur
test
refer
standard
pool
sensit
direct
antigen
detect
pneumonia
urin
adult
cap
confid
interv
ci
specif
ci
children
pneumococc
antigen
urin
less
specif
invas
infect
detect
children
nasopharyng
colon
similarli
children
pneumonia
detect
h
influenza
type
b
antigen
urin
potenti
diagnost
valu
transient
antigenuria
may
follow
immun
h
influenza
type
b
conjug
vaccin
evalu
adult
low
sensit
physician
consid
follow
neg
rapid
influenza
antigen
test
sensit
test
particularli
specimen
collect
time
high
influenza
preval
rapid
antigen
test
rsv
also
avail
may
similarli
aid
patient
triag
infect
control
antibiot
manag
particularli
pediatr
patient
sensit
specif
rsv
rapid
antigen
test
rang
respect
caus
lower
respiratori
tract
infect
suggest
detect
quantit
humor
eg
antibodi
respons
pathogen
addit
latent
tb
infect
ltbi
diagnos
detect
cellular
immun
respons
tuberculosi
antigen
releas
assay
igra
serolog
test
use
commonli
identifi
infect
due
pathogen
difficult
detect
convent
method
evalu
cours
infect
determin
natur
infect
primari
infect
versu
reinfect
acut
versu
chronic
infect
serolog
test
igra
less
sensit
patient
compromis
immun
system
therefor
use
rule
infect
possibl
microbiolog
cultur
nat
respiratori
secret
lung
tissu
perform
detect
confirm
presenc
pathogen
immunosuppress
patient
may
abl
mount
antibodi
cellmedi
immun
respons
serolog
method
commonli
use
diagnost
laboratori
includ
enzym
immunoassay
immunoprecipit
immunodiffus
id
complement
fixat
cf
immunoblot
includ
western
blot
agglutin
hemagglutin
inhibit
indirect
immunofluoresc
assay
serolog
result
often
express
titer
invers
greatest
dilut
lowest
concentr
patient
serum
retain
measur
specif
antibodyantigen
reactiv
eg
dilut
titer
fourfold
greater
rise
antibodi
titer
acut
convalesc
sera
usual
requir
diagnosi
elev
pathogenspecif
igm
antibodi
titer
singl
serum
sampl
suggest
recent
infect
fall
titer
provid
support
etiolog
signific
organ
howev
falseposit
immunoglobulin
ig
antibodi
test
rare
thu
serolog
test
pathogenspecif
igg
antibodi
acut
convalesc
sera
remain
approach
establish
specif
microbi
caus
infect
variou
commerci
assay
avail
detect
specif
igm
andor
igg
antibodi
respiratori
tract
pathogen
assay
use
support
confirm
diagnosi
bacteri
infect
caus
c
pneumonia
legionella
speci
f
tularensi
pesti
c
trachomati
c
pneumonia
c
psittaci
coxiella
burnetii
although
antibodi
test
commonli
use
detect
infect
pneumonia
recent
studi
unabl
distinguish
infect
asymptomat
colon
organ
diagnosi
c
pneumonia
infect
also
problem
addit
earli
diagnosi
invas
pulmonari
aspergillosi
pool
diagnost
sensit
ci
specif
ci
proven
case
invas
aspergillosi
report
sensit
specif
rang
respect
variou
patient
group
platelia
aspergillu
test
biorad
laboratori
hercul
ca
commerci
avail
assay
detect
galactomannan
fumigatu
flavu
niger
versicolor
terr
shown
yield
posit
result
earli
stage
infect
posit
neg
predict
valu
highrisk
patient
test
biweekli
howev
assay
may
cross
react
histoplasma
p
brasiliensi
penicillium
paecilomyc
alternaria
cryptococcu
falseposit
galactomannan
antigen
assay
result
observ
patient
receiv
certain
food
intraven
piperacillintazobactam
amoxicillin
ticarcillin
cross
reactiv
listeria
monocytogen
also
report
bal
fluid
specimen
lung
transplant
recipi
also
evalu
test
aspergillu
galactomannan
detect
assay
sensit
specif
note
plasmalyt
baxter
intern
inc
deerfield
il
solut
commonli
use
perform
bal
found
yield
falseposit
result
platelia
aspergillu
test
overal
assay
galactomannan
show
promis
current
singl
posit
result
limit
valu
cross
reactiv
common
anoth
fungal
antigen
use
diagnosi
invas
fungal
infect
compon
outer
cell
wall
saprophyt
pathogen
fungi
except
zygomycet
mucor
rhizopu
speci
cryptococcu
speci
antigen
detect
serum
bodi
fluid
patient
invas
aspergillosi
invas
candidiasi
infect
caus
fusarium
acremonium
trichosporum
scedosporium
saccharomyc
p
jirovecii
metaanalysi
diagnosi
invas
fungal
infect
show
pool
sensit
ci
specif
ci
use
differ
assay
cutoff
valu
may
result
differ
sensit
specif
among
variou
commerci
avail
assay
detect
antigen
diagnosi
pneumocysti
pneumonia
hivposit
patient
sensit
assay
specif
pneumocysti
pneumonia
level
correl
organ
burden
pneumocysti
pneumonia
sever
respons
therapi
cross
reactiv
assay
report
use
cotton
gauz
swab
pack
pad
spong
wound
care
surgeri
cellulos
filter
hemodialysi
patient
variou
antimicrobi
agent
includ
piperacillintazobactam
rapid
antigen
test
influenza
b
commonli
use
ambulatori
inpati
set
rapid
detect
influenza
critic
allow
prompt
treatment
antivir
agent
reduc
risk
transmiss
implement
infect
control
practic
reduc
inappropri
use
antibiot
metaanalysi
evalu
studi
differ
rapid
influenza
antigen
test
report
sensit
ci
specif
ci
mediastin
fibrosi
commerci
avail
serolog
test
blastomycosi
exist
suffer
limit
accuraci
minim
valu
patient
care
serolog
test
also
use
diagnosi
parasit
infect
especi
paragonimu
gondii
stercorali
diagnosi
extraintestin
e
histolytica
diseas
serolog
test
play
especi
import
role
screen
prospect
organ
transplant
recipi
patient
consid
immunosuppress
therapi
serolog
test
play
limit
role
aid
diagnosi
respiratori
viral
infect
although
detect
recent
respiratori
viru
infect
exampl
influenza
may
determin
via
seroconvers
fourfold
greater
rise
antibodi
titer
convalesc
rel
acut
serum
sampl
requir
two
tempor
distinct
specimen
make
serolog
result
unlik
factor
clinic
decis
make
contrast
routin
cmv
serolog
test
transplant
donor
recipi
provid
valuabl
inform
risk
subsequ
cmvrelat
sequela
includ
develop
respiratori
diseas
igra
vitro
assay
use
measur
tcell
respons
tuberculosisspecif
antigen
two
fdaapprov
commerci
igra
current
avail
quantiferontb
gold
intub
assay
qftgit
qiagen
carnegi
australia
tspottb
assay
oxford
immunotec
abingdon
unit
kingdom
igra
develop
altern
tuberculin
skin
test
tst
diagnosi
ltbi
compar
tst
igra
improv
specif
distinguish
respons
due
bacillu
bcg
vaccin
latent
tb
infect
antigen
use
igra
absent
strain
bcg
also
compar
tst
igra
offer
logist
advantag
depend
accur
intraderm
inject
patient
return
health
facil
result
read
howev
like
tst
igra
distinguish
ltbi
activ
diseas
sensit
igra
cultureposit
activ
tb
case
rang
sensit
patient
ltbi
progress
activ
tb
rang
igra
tst
shown
similar
sensit
adult
lowand
middleincom
countri
howev
accuraci
igra
test
appear
falter
borderlin
level
posit
studi
conduct
health
care
worker
lowincid
set
shown
highli
variabl
igra
result
serial
test
rate
convers
neg
posit
result
use
manufacturerand
cdcrecommend
cutoff
iuml
rang
rate
revers
posit
neg
result
rang
borderlin
result
around
assay
cutoff
like
revert
convert
final
limit
use
igra
igra
result
proven
use
monitor
respons
tb
treatment
similarli
igra
abl
tst
predict
patient
posit
result
go
develop
activ
tb
current
therefor
igra
use
altern
tst
especi
subject
popul
high
incid
bcg
vaccin
instanc
infect
tuberculosi
commerci
serolog
test
shown
inconsist
imprecis
basi
world
health
organ
polici
statement
advis
use
exist
serolog
test
tb
pneumonia
infect
often
diagnos
presenc
specif
antibodi
serum
cold
agglutinin
detect
agglutin
type
rhneg
red
blood
cell
c
present
sera
approxim
patient
pneumonia
infect
level
declin
baselin
within
week
acut
infect
howev
cold
agglutinin
nonspecif
antibodi
chloroformmethanol
glycolipid
extract
pneumonia
detect
cf
test
cultureposit
patient
singl
elev
titer
greater
greater
fourfold
rise
titer
acut
convalesc
sera
requir
establish
diagnosi
enzym
immunoassay
detect
igm
iga
antibodi
specif
recogn
pneumonia
membran
protein
develop
improv
sensit
specif
cf
assay
specif
igm
antibodi
appear
first
week
ill
reach
peak
titer
third
week
howev
igm
antibodi
pneumonia
consist
produc
adult
prior
sensit
neg
igm
result
rule
acut
pneumonia
infect
particularli
older
adult
detect
specif
iga
antibodi
serum
shown
one
group
reliabl
approach
diagnosi
antibodi
also
produc
earli
cours
diseas
reliabl
present
infect
individu
regardless
age
other
howev
found
littl
valu
serolog
test
play
import
role
diagnosi
fungal
respiratori
tract
infect
due
c
immiti
h
capsulatum
c
immiti
diagnosi
infect
base
detect
antibodi
antigen
deriv
coccidioid
mycelia
spherul
although
may
cross
reactiv
yeast
dimorph
fungi
antibodi
c
immiti
detect
id
cf
enzym
immunoassay
precipitinspecif
igm
antibodi
develop
individu
within
week
primari
c
immiti
infect
subsequ
disappear
except
patient
dissemin
infect
complementfix
igg
antibodi
appear
later
persist
relat
sever
diseas
declin
diseas
remiss
titer
higher
suggest
possibl
dissemin
infect
sensit
serolog
test
drop
immunocompromis
host
compar
immunocompet
patient
h
capsulatum
serum
antibodi
detect
cf
use
yeast
myceli
antigen
id
assay
show
increas
titer
patient
pulmonari
histoplasmosi
approxim
dissemin
diseas
cf
test
sensit
less
specif
id
test
diagnosi
subclin
acut
pulmonari
histoplasmosi
antibodi
becom
detect
first
cf
week
histoplasma
infect
id
week
later
howev
id
test
remain
posit
longer
cf
test
resolut
infect
becom
neg
year
later
antibodi
level
remain
high
chronic
pulmonari
infect
progress
dissemin
diseas
complet
refer
list
avail
expertconsult
mackowiak
thank
stanford
patholog
resid
natalia
isaza
albert
tsai
lee
frederick
schroeder
contribut
chapter
diagnost
test
order
result
alter
treatment
decis
clinician
play
critic
role
prevent
accident
laboratori
exposur
notifi
microbiolog
laboratori
highli
virul
transmiss
agent
suspect
caus
diseas
syndrom
order
set
improv
accuraci
effici
test
select
thu
facilit
accur
diagnosi
infecti
diseas
lower
respiratori
tract
secret
collect
oropharynx
nearli
alway
contamin
resid
microflora
oral
caviti
therefor
microscopi
cultur
nucleic
acid
test
result
must
interpret
context
clinic
evid
diagnost
find
nucleic
acid
test
facilit
rapid
accur
diagnosi
lower
respiratori
tract
infect
especi
caus
virus
pathogen
difficult
cultur
